DARE — Dare Bioscience Share News
0.000.00%
Last trade - 00:00- $12.70m
- $5.98m
- $1.03m
Dare Bioscience Inc expected to post a loss of 58 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Tesla, General Motors, Chevron
Daré Bioscience soars on birth control device trial data
Dare Bioscience Inc reports results for the quarter ended March 31 - Earnings Summary
Focus: FDA upheaval pushes some biotech firms to plan early trials out of US
Brief: Daré Bioscience Reports First Quarter 2025 Financial Results And Provides Company Update
Dare Bioscience Inc expected to post a loss of 58 cents a share - Earnings Preview
Dare Bioscience Inc expected to post a loss of 58 cents a share - Earnings Preview
Dare Bioscience Inc reports results for the quarter ended December 31 - Earnings Summary
Brief: Daré Bioscience Reports Full Year 2024 Financial Results
Dare Bioscience Inc expected to post a loss of 53 cents a share - Earnings Preview
Dare Bioscience Inc expected to post a loss of 53 cents a share - Earnings Preview
Brief: Daré Bioscience Announces $2.5 Million Grant Funding Installment To Support Further Development Of Novel Contraceptive Technology DARE-LARC1
Brief: Dare Bioscience Files Prospectus For Resale Of Up To 2.8 Million Shares Of Common Stock By Selling Stockholder - SEC Filing
Dare Bioscience Inc reports results for the quarter - Earnings Summary
Brief: Daré Bioscience Announces Grant To Support Development Of A Novel Non-Hormonal Contraceptive Candidate And Expansion Of Ovaprene Pivotal Study Clinical Trial Sites
Dare Bioscience Inc expected to post a loss of 73 cents a share - Earnings Preview
Dare Bioscience Inc expected to post a loss of 73 cents a share - Earnings Preview
Brief: Daré Bioscience Announces Common Stock Purchase Agreement For Up To $15 Million With Lincoln Park Capital Fund, Llc